Background: The aim of this study was to describe the prevalence and prognostic value of the most common triggering factors in acute heart failure. Methods: Patients with acute heart failure from 41 Spanish emergency departments were recruited consecutively in three time periods between 2011 and 2016. Precipitating factors were classified as: (a) unrecognized; (b) infection; (c) atrial fibrillation; (d) anaemia; (e) hypertension; (f) acute coronary syndrome; (g) non-adherence; and (h) two or more precipitant factors. Unadjusted and adjusted logistic regression models were used to assess the association between 30-day mortality and each precipitant factor. The risk of dying was further evaluated by week intervals over the 30-day follow-up to assess the period of higher vulnerability for each precipitant factor. Results: Approximately 69% of our 9999 patients presented with a triggering factor and 1002 died within the first 30 days (10.0%). The most prevalent factors were infection and atrial fibrillation. After adjusting for 11 known predictors, acute coronary syndrome was associated with higher 30-day mortality (odds ratio (OR) 1.87; 95% confidence interval (CI) 1.02-3.42), whereas atrial fibrillation (OR 0.75; 95% CI 0.56-0.94) and hypertension (OR 0.34; 95% CI 0.21-0.55) were significantly associated with better outcomes when compared to patients without precipitant. Patients with infection, anaemia and non-compliance were not at higher risk of dying within 30 days. These findings were consistent across gender and age groups. The 30-day mortality time pattern varied between and within precipitant factors. Conclusions: Precipitant factors in acute heart failure patients are prevalent and have a prognostic value regardless of the patient's gender and age. They can be managed with specific treatments and can sometimes be prevented. Original scientific paper 5581 (56.1%) Comorbidities Hypertension, n (%) 8408 (84.2%) Diabetes mellitus, n (%) 4145 (41.5%) Ischaemic heart disease, n (%) 2846 (28.5%) Atrial fibrillation, n (%) 5026 (50.3%) Chronic kidney disease (creatinine >2 mg/dL), n (%) 2656 (26.6%) Cerebrovascular disease, n (%) 1321 (13.2%) Peripheral artery disease, n (%) 938 (9.4%) Chronic obstructive pulmonary disease, n (%) 2411 (24.1%) Dementia, n (%) 1326 (13.3%) Cancer, n (%) 1365 (13.7%) Previous episodes of acute heart failure, n (%) 5727 (57.8%) Long-term treatments at home Diuretic, n (%) 6385 (65.7%) Beta-blocker, n (%) 4099 (42.2%) Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, n (%) 5546 (55.5%) Mineralocorticoid receptor antagonist, n (%) 1610 (16.6%) Digoxin, n (%) 1470 (15.2%) Clinical data at arrival Systolic blood pressure (mm Hg), mean (SD) 141.5 (27.6) Heart rate (bpm), mean (SD) 89.1 (23.9) Respiratory rate (bpm), mean (SD) 22.6 (6.6) Oxygen saturation, mean (SD) 92.2 (6.6) NYHA class IV, n (%) 4382 (43.8%) Left ventricular ejection fraction before admission (%), mean (SD) 51.7 (15.2) Barthel index on arrival, mean (SD) 64.4 (29.3) Laboratory and ECG data Haemoglobin (g/L) (mean (SD)) 12.0 (2.1) Glucose (mg/dl) (mean (SD)) 149.1 (86.1) Creatinine (mg/dl) (mean (SD)) 1.3 (0.8) NT-proBNP (pg/mL) (median, IQR) 3883 (1899, 8322) Elevated troponin, n (%) 990 (58.4%) Left ventricular hypertrophy, n (%) 345 (3.5%) Left bundle branch block, n (%) 893 (9.2%) Management at emergency department Oxygen, n (%) 7136 (71.9%) Mechanical ventilation, n (%) 646 (6.5%) Morphine, n (%) 608 (6.1%) Diuretic, n (%) 8427 (84.8%) Data at discharge Length of stay (days) (median, IQR) 5 (1, 10) Admission, n (%) 7588 (76.0%)
Introduction
Although much progress has been made in the treatment of chronic heart failure, little has changed in the management of acute heart failure (AHF) over past decades. [1] [2] [3] Consequently, mortality for patients with AHF remains unacceptably high. 4, 5 However, not all patients face the same likelihood of presenting with poor outcomes and several risk scores have been developed to stratify the prognosis of patients with AHF better. [4] [5] [6] Most of them do not include predictors regarding the presence of precipitating factors, despite the fact that their prompt identification and early medical management may have an impact on clinical outcomes. 7 Instead of a specific disease, AHF is a clinical syndrome defined by changes in symptoms and/or signs and therefore includes a broad spectrum of phenotypes, and can be triggered by a wide variety of precipitant factors. In the light of recent clinical trials showing a lack of benefit using novel pharmacological approaches, [8] [9] [10] further attention has to be paid to the heterogeneity of AHF presentations (in AHF 'one size does not fit all'). As well as focusing on therapies to reduce congestion and improve the pump function, there is an increasing interest in identifying those precipitant factors that can be either prevented (i.e. non-compliance) or treated accordingly (i.e. infection). 11 Furthermore, current recommendations for the management of AHF advise the identification of triggering factors of AHF in order specifically to treat the cause(s) of the acute episode. 12, 13 To date, there have been few studies evaluating the prevalence and prognostic value of precipitant factors in AHF patients, and most of them have a substantial selection bias given that they have only included hospitalised patients. 14 Using a large representative cohort of AHF patients recruited at the emergency department (ED), this study aimed to: (a) describe the prevalence of precipitant factors and the clinical profile of AHF patients by each triggering factor; (b) evaluate the prognostic value of each precipitant factor through the assessment of its association with 30-day mortality; (c) study whether the prognostic implications of the precipitating factors may vary across gender or age groups; and (d) evaluate whether the risk of dying after presenting with each precipitant factor is constant over time or varies within and between precipitant factors.
Methods

Study population
The PAPRICA-4 (acronym for the Spanish words 'PApel de los PRecipitantes de episodios de Insuficiencia Cardiaca Aguda'; that means in English 'role of precipitants of AHF') study belongs to a set of exploratory analyses for the evaluation of precipitant factors within the Epidemiology of Acute Heart Failure in Emergency Departments (EAHFE) registry. 7, 15 The EAHFE is an observational cohort study involving data collection on AHF patients in 41 Spanish EDs. This registry collects information in periods of 1-2 months between intervals of 2-3 years. The only exclusion criterion is to develop AHF concurrently with an ST-segment elevation myocardial infarction (STEMI), approximately 3%, as the vast majority of these subjects by-passes the ED going straight to the cath lab. Participating centres are a composition of tertiary and non-tertiary hospitals, therefore representing a broad spectrum of EDs across the country.
In this study, we used data from patients recruited in three separate cohorts within the EAHFE registry: November to December 2011 (cohort 3), January to February 2014 (cohort 4) and January to February 2016 (cohort 5), thus providing a pool of 11,360 AHF episodes. Details of the design and conduct of the EAHFE have previously been published elsewhere. 5, 16 Briefly, patient inclusion is performed by the attending emergency physician using the Framingham clinical diagnostic criteria 17 and confirmed by the principal investigator of each centre to ensure that all patients fulfilled the clinical diagnostic criteria of AHF. The diagnosis was confirmed by natriuretic peptide determinations or echocardiography following the European Society of Cardiology (ESC) criteria 12 for approximately 92% of patients.
Precipitating factors and 30-day mortality
The classification of precipitating factors was: (a) unrecognised; (b) infection; (c) atrial fibrillation (AF); (d) anaemia; (e) hypertension; (f) non-ST elevation acute coronary syndrome (NST-ACS); (g) non-adherence (diet, medications or iatrogenic); and (h) two or more precipitant factors. These factors were prospectively collected in the case report form, as per local investigator clinical judgement. According to their initial clinical presentation, patients were assigned to one or more precipitating factors by the recruiting clinician. The following definitions were used for the precipitant factors, respectively: (a) no factor recognised; (b) active infection, of any system, considered to have a role in acute decompensation; (c) mean heart rate greater than 100 bpm with AF; (d) haemoglobin less than 80 g/L; (e) systolic blood pressure greater than 180 mmHg; (f) symptoms of ACS starting before decompensation, and not developing after the appearance of dyspnoea; (g) high water or sodium intake, omission to take drugs prescribed for heart failure treatment; and (h) when two or more factors concur, but none is of sufficient magnitude to explain the decompensation by itself.
All-cause 30-day mortality was recorded during hospitalisation and subsequent follow-up through telephone contact and careful evaluation of medical records between 1 and 3 months after the index AHF episode. A blinded investigator from each centre assessed events at follow-up for all patients admitted at the relevant hospital.
AHF-MEESSI risk score for covariate adjustment
To evaluate the association between precipitant factors and 30-day mortality, a set of predictors from a risk model already derived from this registry was used for covariate adjustment in multivariate models. Details of the development and previous validation of the Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF (MEESSI-AHF) risk score have been described elsewhere. 5 Briefly, the score is made up of 13 predictors that were originally identified from 88 candidate variables to predict 30-day all-cause mortality in patients presenting with AHF to the ED. In the final model, each continuous variable was incorporated into several ordered categories to facilitate its use in practice, and a website calculator was implemented to facilitate calculations (http:// meessi-ahf.risk.score-calculator-ica-semes.portalsemes.org/). This model has been validated at a national 18 and international level 19 in separate cohorts. Risk factors included in these model are: Barthel index score at ED visit, 16 age, systolic blood pressure, New York Heart Association (NYHA) class IV, potassium level, NT-proBNP, troponin level, low output symptoms, respiratory rate, oxygen saturation, ACS, creatinine level and hypertrophy on ECG. Using these already known predictors, multivariate models assessing the association between precipitant factors and 30-day mortality were adjusted for 11 out of these 13 predictors, excluding systolic blood pressure and ACS given that they were inherently related to some precipitant factors.
Ethical standards
The present study followed the Declaration of Helsinki on ethical principles for medical research involving human subjects, and patients gave written informed consent to participate and to be contacted for follow-up. The protocol was approved by the ethics committee at the Hospital Universitario Central de Asturias (Oviedo) Spain, with reference numbers 69/2011, 166/13 and 160/15.
Statistical analysis
Continuous variables were summarised by mean ± standard deviation (SD) or median (interquartile range; IQR) if highly skewed. Categorical variables are represented by frequencies and percentages. Baseline comparisons were performed using one-way analysis of variance (ANOVA), Kruskal-Wallis test or chi-square tests, as appropriate.
Event-free survival for 30-day cumulative mortality was plotted using the Kaplan-Meier method and univariate associations were compared using the log-rank test. Follow-up started at the time of the ED arrival. Univariate and multivariate logistic regression models were produced for each precipitant factor. The covariates considered in the multivariate regression model were the 11 risk predictors described below in the MEESSI-AHF risk score and the relevant precipitant factor of interest, which were forced into the model. To account for missingness of the covariates, a multiple imputation technique was applied using chained equations. Fifty imputed datasets were produced to deal with missingness in the 11 variables included in the adjusted model (Barthel index, age, NYHA class IV, potassium level, NT-proBNP, troponin level, low output symptoms, respiratory rate, oxygen saturation, creatinine level, and hypertrophy on ECG) as well as for precipitant factors, the cohort and the outcome. Adjusted odds ratios (ORs) and their 95% confidence intervals (CIs) were therefore estimated using these imputed data. Two separate subgroup analyses for gender and age were performed using multivariate logistic models adjusted for the 11 risk factors and including: (a) the terms gender, precipitant factors and their interaction (gender * precipitant factor); and (b) the terms age, precipitant factors and their interaction (age * precipitant factor). P values for interaction were reported accordingly.
To evaluate the risk of dying by intervals of time, we split the follow-up time into four categories (week 1, W1; week 2, W2; week 3, W3; and week 4 and the remaining 2 days until completing 30 days; W4+) and performed a nonparametric approach using life table estimates of the survival curve. Within each precipitant factor, we evaluated the variation of the hazard of death across intervals of follow-up, obtaining a hazard function for each follow-up interval within each precipitant factor. Given the population alive at the starting point of each interval, the hazard function is the proportion of the population that will die in the next interval, divided by the length of the interval (i.e. one week for W1). The units of the hazard function, also known as conditional mortality rate, are deaths per 1000 person-days.
Differences were considered statistically significant at P<0.05. All statistical analyses were performed using STATA version 15.1 (Stata Corp, College Station, TX, USA). Some figures were produced in GraphPad Prism 6.00 (GraphPad Software, La Jolla, CA, USA).
Results
Study population
A total of 9999 patients were included in this analysis (Figure 1 ), thus excluding 1361 individuals (12.0%) because of the lack of information on precipitant factors (1330 patients) or follow-up (31 subjects). The mean age was 80.7 years (SD 9.9 years) and 56% were women. Among the population cohort, 84% of patients had systemic hypertension, 42% had diabetes mellitus, 29% had ischaemic heart disease, 50% had atrial fibrillation and 58% had a previous episode of AHF. Other data regarding baseline and acute clinical status, ECG, laboratory results and ED management are shown in Table 1 .
Distribution of AHF precipitating factors
Precipitating factors of AHF were identified in 6872 subjects (68.7%), whereas no triggering factor was recognised in the remaining 3127 patients (31.3%). Among those with precipitant factors, one single precipitant was identified in 5757 patients (83.8%), while a combination of two or more precipitants were identified in 1115 subjects (16.2%).
Among those 5757 patients with one single identified precipitant, infection (n=3270, 56.8%) was the most common cause, followed by AF (n=1160, 20.2%), anaemia (n=481, 8.4%), hypertension (n=474, 8.2%), non-compliance (n=284, 4.9%) and NST-ACS (n=89, 1.6%). Of note, STEMI patients were excluded from this cohort. Substantial differences were observed in baseline characteristics as well as in the acute episode and management between precipitating factors (Tables 2 and 3 , respectively).
Association between precipitating factors and 30-day mortality
Among the 9999 patients, 1002 died within the first 30 days (10.0%). There were no differences in mortality across our three periods of data collection: 303 deaths (10.3%) in cohort 3 (n=2982 patients), 278 deaths (9.7%) in cohort 4 (n=2865 patients) and 416 deaths (10.0%) in cohort 5 (n=4152 patients); P=0.728. The Kaplan-Meier survival curves in Figure 2 and the forest plot in Figure 3 show the univariate association between each precipitating factor and the 30-day mortality outcome. Notably, patients admitted to the ED with infection (hazard ratio (HR) 1.18; 95% CI 1.01-1.39; P=0.036) and NST-ACS (HR 3.03; 95% CI 1.84-4.97; P<0.001) were associated with poorer outcomes. Similarly, the combination of two or more precipitant factors was also related to 30-day mortality (HR 1.35; 95% CI 1.09-1.66; P=0.006). In contrast, patients with AF (HR 0.66; 95% CI 0.51-0.86; P=0.002), hypertension (HR 0.53; 95% CI 0.27-0.67; P<0.001) and lack of compliance (HR 0.51; 95% CI 0.30-0.88; P=0.014) showed a reduced 30-day risk of death compared with patients without a recognised precipitant. In the middle ground, anaemia has no impact on 30-day mortality when compared to those patients with unidentified precipitant (HR 0.95; 95% CI 0.68-1.32; P=0.767). Further Kaplan-Meier curves comparing patients with each precipitant factor versus the overall remaining cohort (not only those with unrecognised precipitant factor) are reported in Supplementary Figure 1 -results were consistent with those reported in Figure 2 .
After adjustment for 11 a priori selected prognostic factors, AHF precipitated by NST-ACS (HR 1.87; 95% CI 1.02-3.42; P=0.043), AF (HR 0.75; 95% CI 0.56-0.99; P=0.046) and hypertension (HR 0.34; 95% CI 0.21-0.55; P<0.001) remained significantly associated with 30-day mortality, whereas AHF triggered by infection, anaemia, non-compliance or the presence of two or more factors had no impact on the outcome after covariate adjustment ( Figure  3) . These associations were fairly consistent between patients with left ventricular ejection fraction (LVEF) of 50% or greater and patients with LVEF less than 50% ( Supplementary  Table 1 ), although care should be taken in their interpretation given that 4554 patients (45.5%) lacked these data. Differences in the distribution of the precipitant factors between women and men as well as differences in mean age across triggering factors were observed in Table 2 . In the univariate analysis, women showed a trend towards a significantly higher 30-day mortality in comparison to men (10.6% vs. 9.5%; P=0.056) and patients over 80 years of age showed higher mortality (13.3% vs. 5.3%; P<0.001). Subgroup analysis according to age and gender were performed and reported in Figure 4 . Importantly, the effect of each precipitant factor was consistent between men and women as well as across age groups, suggesting that the association of each precipitant factor with mortality is similar regardless of gender and age. Of note, age was split into two categories by its median to report subgroup findings, although no interactions were found when it was split into tertiles (data not shown).
Patterns of mortality within the first 30 days by precipitant factors
The distribution of mortality within the first 30 days, as well as the variation in the risk of death across time (hazard function), was reported for each precipitant factor in Figure 5 . Most triggering factors showed a decreasing proportion of deaths and risk over time (i.e. infection). However, others show a similar proportion of deaths and risk as time goes by (i.e. non-compliance factor) and others revealed a higher proportion of deaths (and risk) at a different interval than the immediate week after the AHF episode -i.e. W2 for NST-ACS and W4+ for hypertension. This information might be useful to identify periods of vulnerability after the index episode. Risk of 30-day mortality expressed as odds ratio (OR) with its 95% confidence interval (CI) in the presence of precipitating factors of acute heart failure compared with the absence of identified precipitating factors. The unadjusted estimates are in red, whereas the estimates in blue have been adjusted for 11 risk predictors included in the MEESSI-AHF risk model. NST-ACS: non-ST elevation acute coronary syndrome.
Discussion
Precipitant factors in AHF can be managed with specific treatments and can sometimes be prevented. 11 In our study, 68.7% of the patients with AHF presented with at least one precipitant factor, infection being the most common. When compared to those patients without a recognised precipitant factor, some of these triggering factors were strongly associated with poor short-term outcome (NST-ACS), whereas others were associated with a better outcome (AF and hypertension). Infection, anaemia, non-compliance or the presence of two or more factors had a similar high risk of dying to those patients without a recognised precipitant factor (30-day mortality approximately 10%). The impact of these triggering factors was consistent across gender and age groups. Importantly, we described the time pattern of mortality after each precipitant factor within the first 30 days of follow-up, and described a varying risk of death for each week of follow-up, which differed between and within factors.
Although current recommendations for the management of AHF advise to identify potential triggering factors in order specifically to treat the cause(s) of the acute episode, 12, 13 their evaluation at the ED has received little attention to date. 14 Our study shows that 68.7% patients with AHF have at least one precipitant factor. Similar to previous studies, infection was the most prevalent precipitant factor. 14 In contrast, the presence of ACS as a precipitant factor is particularly low in our study in comparison to previous reports, such as the Global Research on Acute conditions Team (GREAT) network 1 or the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTMIZE-HF) study. 20 This disagreement can be explained by three factors: (a) ACS was underrepresented in our cohort because STEMI patients were excluded; (b) ACS patients were overrepresented in those cohorts mostly recruiting patients from cardiology, intensive care and coronary units; 1, 20 and (c) other studies have shown some degree of selection bias due to the exclusion of non-hospitalised AHF individuals -patients directly discharged from the ED represent approximately 16-36% of AHF patients 4 and are not captured in most of the previous reports. 14 This explains why in GREAT, the prevalence of AHF precipitants was approximately 45%, 1 much lower than ours (68.7%).
In this study, we have shown that some of the triggering factors are associated with higher 30-day mortality (NST-ACS), whereas others were significantly associated with better outcomes (AF and hypertension) or showed a trend towards less mortality (non-compliance), when compared to those patients without a recognised precipitant factor. However, it has to be highlighted that patients with unrecognised precipitant factors already had a high 30-day mortality (approximately 10%) with a similar risk for poor outcomes to patients with infection and anaemia. In other words, we might rather say that patients with AF and hypertension were at 'low risk' for 30-day mortality, whereas patients with unrecognised factors, infection or anaemia were at 'intermediate risk' and patients with NST-ACS were at the higher risk on the scale. Importantly, these findings were consistent between women and men and between younger and older patients.
There are several prognostic models predicting shortterm outcomes in this setting, although few of them include precipitant factors within their predictors. The MEESSI-AHF risk score includes NST-ACS as a predictor, 5, 18, 19 whereas a predictive model developed by Lee et al. showed that anaemia was a one-year predictor, but not of 30-day mortality. 6 Similarly, Harjola et al. reported a higher risk for death at 3-12 months post-discharge, but not at the immediate 3 months post-discharge. 21 This highlights the theory that some precipitant factors may have an additive prognostic value on top of risk scores (as demonstrated by those factors which remained independently associated with 30-day mortality after adjustment for the MEESSI-AHF risk score) as well as the idea that risk of death might vary over time by precipitant factors.
The assessment of the time course of the risk of death according to precipitating factors has already been reported by Arrigo et al. in another cohort. 1 The novelty of our results lies in two capital issues: (a) the starting point of our follow-up is the ED admission instead of the hospital admission, hence we captured the whole 'universe' of AHF patients and started their follow-up before the patient was clinically managed from the ED; and (b) we report the 'absolute' hazard for each precipitant factor, instead of the relative hazard (or HR) compared to patients with unrecognised factors. Given that having an unrecognised triggering factor is already associated with high mortality (actually, only AF and non-adherence were 'protective'), we believe that the information about risk was better captured in absolute terms within each precipitant factor. Moreover, having an 'unrecognised' precipitant factor does not provide a fair comparative group, given that it might include a variety of unknown but latent precipitant factors. Notably, the risk of dying declines over time in most precipitant factors, although some of them have a more stable risk period (i.e. hypertension and non-compliance), whereas NST-ACS has peak of risk on the second week. This information might be valuable to assess the period of higher vulnerability after an AHF episode for each triggering factor.
The importance of identifying precipitant factors triggering AHF has been generally overlooked despite their vast clinical relevance. Although we lack information about whether certain precipitant factors (or lack of triggering factor) would require a more intensive monitoring and therapy, we can be certain that the identification of precipitant factors leading to AHF should be managed addressing their specific cause. Hence, the coexistence of ACS and AHF requires an immediate (<2 hours from hospital admission in NST-ACS) invasive strategy aimed to revascularise the culprit vessel, as recommended by the ESC guidelines. 12 In the case of a hypertensive emergency, a prompt reduction in blood pressure with intravenous vasodilators in combination with loop diuretics should be started as soon as possible. 22 Tachyarrhythmias in AHF patients can be managed using adequate anti-arrhythmic therapy or electrical cardioversion. 23 For infections, adequate antibiotic therapy and hospitalisation can avoid poor short-term outcomes. 15 Noncompliance with treatment and diet offers an opportunity to correct unhealthy habits and increase patient self-control of their disease. Anaemia can be specifically treated with either transfusion or intravenous iron infusion. Importantly, most of these measures to cope with triggering factors can be initiated in the ED and therefore have a potential impact on clinical outcomes.
Limitations
Several considerations are important in interpreting our findings. This study has limitations inherent to an analysis of observational data: the association between precipitant factors and 30-day mortality cannot be interpreted as a causal relationship. To avoid inaccuracies, a single precipitant factor was identified per AHF episode, whereas those patients with more than one precipitant factor were grouped together and were not evaluated in detail. The prognostic value of the triggering factors is in line with previous publications. 1 The non-adherence to diet or treatment triggering factor might be underdiagnosed if we take into account that the ED is not the optimal place to enquire in detail about diet and treatment adherence. Importantly, we did not track patients to evaluate whether their precipitant factor(s) received specific treatment over the 30-day follow-up. Moreover, we did not collect information on other relevant precipitant factors, such as renal failure, acute mechanical complications, pulmonary embolism, or haze. 12, 24 In contrast, the strength of our study lies in including a large number of patients from 41 hospitals (tertiary and non-tertiary) admitted at the ED, thus removing the selection bias from most studies recruiting hospitalised patients, and making our findings generalisable to other populations.
Conclusions
Precipitant factors in AHF patients are prevalent (approximately 69%) and have a prognostic value regardless of the gender and age of the patient. Importantly, they can be managed with specific treatments and can sometimes be prevented. Moreover, their impact on mortality varies over time within the first month from one triggering factor to another, which brings to light the periods of higher vulnerability after the AHF index episode for each precipitant factor. Further studies are needed to evaluate the impact on clinical outcomes of managing precipitant factors with their specific treatment as well as applying different criteria for hospitalisation or discharge directly from the ED for each triggering factor.
